Company Mosaic ImmunoEngineering, Inc.

Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company. The Company is focused on developing and commercializing its immunomodulator platform technology. The Company’s core technology platform is based on Cowpea mosaic virus (CPMV), which is non-infectious to humans or other animals but upon intra-tumoral administration, elicits an innate immune response resulting in potent antitumor activity against the primary and distant tumor sites. The Company’s lead immunotherapy product candidate, MIE-101, is based on a naturally occurring plant virus known as CPMV. The product is injected directly into a tumor and can act as an in-situ vaccine using markers of the injected tumor as the target which results in the activation of an immune response against the primary tumor and to prime systemic anti-tumor immunity, while reversing immunosuppressive signals in the tumor microenvironment (TME). MIE-101 is used for the treatment of many different types of cancer.

Number of employees: 6